Abstract Vascular endothelial cells respond to external stimuli by altering the secretion of several bioactive molecules, including von Willebrand factor (vWf), prostacyclin (PGI P ) and nitric oxide (NO). The release of all three molecules is regulated by a rise in cytosolic calcium ([Ca 2+ ] i ). In the present study we investigated whether cAMP-dependent signaling provides differential regulation of these effector systems by modulating the effect of [Ca 2+ ] i in cultured human endothelial cells. The stable PGI P analog iloprost, like other cAMP-raising agents (forskolin and adenosine), caused an acute dose-dependent increase in vWf release and potentiated the secretory response to thrombin. In contrast, iloprost, forskolin and adenosine failed to induce PGI P release and inhibit thrombin-induced release. Our findings indicate cAMP-raising agents have opposite effects on [Ca 2+ ] imediated vWf secretion and PGI P release. PGI P may potentiate vWf release and inhibit its own release in an autocrine manner.
Introduction
Vascular endothelial cells respond to external stimuli by altering the secretion of several bioactive molecules, including von Willebrand factor (vWf), prostacyclin (PGI P ) and nitric oxide (NO). vWf is released by exocytosis from specialized secretory granules called Weibel-Palade bodies [1] . Exocytosis in response to thrombin and several other agonists is mediated by a rise in cytosolic calcium ([Ca P ] i ) and activation of a calmodulin-dependent signaling pathway [2] . vWf release can also be induced by phorbol esters, suggesting a role for protein kinase C (PKC). However, thrombin-induced vWf release is not prevented by PKC inhibitors [3] . Thus, a rise in [Ca P ] i is thought to be the main signaling event for exocytosis. Prostacyclin production, via the activation of phospholipase A2, is also a calcium-dependent process. In addition it is modulated by protein tyrosine kinases and possibly by PKC [4, 5] . NO synthesis is also driven by a rise in [Ca P ] i . Calcium/calmodulin directly binds endothelial nitric oxide synthase (eNOS) and stimulates NO synthesis in the vicinity of the plasma membrane, where eNOS is associated with discrete membrane structures called caveolae [6] . Thus, a rise in [Ca P ] i is a key signaling event for three di¡erent e¡ector systems in a single cell type. Given the di¡erent physiological functions of these e¡ector systems, it is very likely that they are regulated in a di¡erential manner. Such di¡erential regulation could be accounted for in part by di¡erent subcellular localization of the calcium signal or by specialization of endothelial cells in different vascular beds. However, additional signaling pathways may provide di¡erential regulation by modulating the e¡ect of [Ca P ] i . We have recently observed that vWf secretion is also regulated by cAMP. Pharmacological agents such as forskolin and 8-bromo-cAMP can induce vWf secretion, and strongly potentiate the secretory response to thrombin [7] . Furthermore, the receptor-mediated agonists epinephrine and adenosine potentiate the response to [Ca P ] i -raising agents such as thrombin and ATP, in a cAMP-dependent manner [7, 8] . Prostacyclin produced by endothelial cells acts via a speci¢c, adenylate cyclase-coupled receptor [9] . Prostacyclin is thought to regulate endothelial permeability via a cAMP-dependent signaling pathway, suggesting a role for prostacyclin in the autocrine regulation of endothelial function [10] . In the present study we investigated the e¡ect of prostacyclin, using its stable analog iloprost, on vWf secretion and on prostacyclin production in cultured human endothelial cells. In addition, since endothelial NO is also an autocrine regulator of endothelial function, we tested the e¡ect of NO on vWf secretion.
Materials and methods

Materials
RPMI 1640 was from Gibco BRL (Gaithersburg, MD, USA), fetal calf serum (FCS) and collagenase were from Seromed (Berlin, Germany). Endothelial cell growth supplement (ECGS) was from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Anti-vWf antibodies were from Dako (Glostrup, Denmark). Iloprost was from Shering (Berlin, Germany). Adenosine was from Fluka (Buchs, Switzerland). Linsidomine (SIN-1) and sodium nitroprusside were from RBI (Natick, MA, USA). Human thrombin, 3-isobutyl-1-methyl-xanthine (IBMX) and forskolin were from Sigma (St. Louis, MO, USA).
Cell culture
Primary cultures of endothelial cells (HUVECs) were obtained from individual human umbilical veins by collagenase digestion as described previously [11] . They were grown in medium RPMI 1640 supplemented with 10% FCS, 90 Wg/ml heparin and 15 Wg/ml ECGS. Cells were used during passages 1 or 2. Tissue culture dishes as well as the multiwell plates (Costar, Cambridge, MA, USA) were coated with 0.1% gelatin.
vWf release studies
Con£uent monolayers of HUVECs grown in 24-well dishes were washed three times and preincubated in Krebs-Ringer-bicarbonate bu¡er (KRBH, 120 mmol/l NaCl, 4.75 mmol/l KCl, 1.2 mmol/l KH P PO R , 0.6 mmol/l MgSO R , 1.2 mmol/l CaCl P , 25 mmol/l NaHCO Q , 25 mmol/l HEPES, pH 7.4) supplemented with 0.1% BSA, and preincubated for 5^10 min at 37³C. After a fourth wash, cells were incubated in KRBH with the di¡erent agents. The collected supernatants were cleared of cell debris by centrifugation (16 000Ug for 60 s) and stored at 320³C for later assay. All pharmacological agents were directly dissolved in the incubation medium, only forskolin and IBMX were dissolved in DMSO. The ¢nal concentration of DMSO in the incubation medium did not exceed 0.2%, a concentration which has no e¡ect on vWf release. vWf was measured in the supernatants by ELISA as described previously [12] . A standard curve was constructed from serial dilutions of normal pooled plasma, assuming a plasma concentration of 10 Wg/ml. Results are usually expressed in ng/ well/time unit.
Prostacyclin release studies
Con£uent HUVECs grown in 12-well dishes were washed three times in KRBH and incubated at 37³C in 1.2 ml KRBH. After 10 min, 0.6 ml was gently removed. The various agonists were then added with minimal shaking. The incubation was continued for the indicated times, and the supernatants were collected for later assays. For both vWf and PGI P , release was calculated as the di¡erence in content between the two successive samples. This procedure was used to minimize the possible e¡ect of mechanical stress (due to cell handling) on PGI P release.
vWf was measured by ELISA. PGI P was measured by a speci¢c radioimmunoassay of its stable metabolite 6-keto-PGF IK as previously described [13] . The agonists tested, in particular iloprost, did not interfere with the immune reaction when added to standard samples. We observed considerable variation in basal PGI P release between cell batches. The results were therefore expressed in relative values, i.e. as a percentage of release from cells stimulated with thrombin (0.5 U/ml) from the same cell preparation. Unless indicated otherwise, results are shown as mean þ S.E.M. Statistical analysis was done using the two-tailed, paired Student's t-test.
Results
E¡ect of iloprost on vWf release from cultured HUVECs
To investigate the e¡ect of prostacyclin on vWf release we employed the stable analog iloprost on vWf release from cultured HUVECs (Fig. 1 ). Iloprost (1 nmol/l to 1 Wmol/l) added for 30 min caused a 1.4-fold increase (from 2.5 þ 0.6 to 3.4 þ 0.6 ng/well/30 min, P = 0.04, n = 5) at the highest concentration. Addition of IBMX alone (100 Wmol/l), which blocks cAMP degradation by inhibiting nucleotide phosphodiesterases, had no e¡ect on vWf release. However, when added together with IBMX, the secretory response to iloprost was clearly potentiated. The maximal response (at 1 Wmol/l) was a 2.5-fold increase in vWf release (from 2.7 þ 0.6 to 6.7 þ 1.1 ng/ well/30 min, P = 0.02), and there was a shift to the left in the dose-response curve, with a secretory response detectable at concentrations of iloprost as low as 10 nmol/l (P = 0.01, n = 5). We also observed a potentiating e¡ect of iloprost on thrombin-induced vWf release. Indeed, the secretory response to thrombin and iloprost added together was greater than the sum of the responses to either agent added alone. Iloprost (1 Wmol/l) caused an increase in vWf release from 9.2 þ 1.2 to 13.9 þ 2.0 ng/well/30 min (P = 0.01) when added to thrombin and from 15.3 þ 2.5 to 27.0 þ 3.8 ng/well/30 min (P = 0.01) when added to thrombin and IBMX.
We next performed a comparative time course study of iloprost-and thrombin-induced vWf secretion (Fig. 2) . The response to thrombin was rapid, reaching signi¢cance already after 5 min, the earliest time point studied. In contrast, iloprost-induced vWf release could be demonstrated only after 10 and 30 min (P 6 0.05 for both time points). The addition of IBMX potentiated the response to iloprost but failed to alter the time course: a signi¢cant but small response was observed after 10 min, and became more obvious only at later time points. This delayed secretory response to iloprost is highly Fig. 1 . E¡ect of iloprost on vWf release: dose response. Con£uent HUVECs grown in 24-well plates were incubated for 30 min at 37³C with increasing concentrations of iloprost (0.001^1 Wmol/l) added alone (squares), or together with 100 Wmol/l IBMX (circles), 0.5 U/ml thrombin (upwards triangles) or IBMX and thrombin combined (downwards triangles). vWf release was measured in the supernatant by ELISA. Results are shown as the mean þ S.E.M. of ¢ve experiments. *P 6 0.05 compared to unstimulated control cells. reminiscent of our previous studies with other cAMP-raising agents such as forskolin and adenosine.
Thrombin has been reported to induce PGI P release from cultured endothelial cells. We therefore wondered whether PGI P released into the incubation bu¡er could mediate in part the secretory response to thrombin. However, thrombin-induced vWf release was not a¡ected by preincubation with the cyclooxygenase inhibitor indomethacin (1^10 Wmol/ l, added for 10^40 min) (not shown).
E¡ect of cAMP-raising agents on vWf secretion and
PGI P release To compare the e¡ect of cAMP-raising agents on vWf secretion and PGI P release, we optimized the incubation conditions to measure both secretory products from the same cell preparation. HUVECs were preincubated for 10 min in 1.2 ml KRBH. After removal of 0.6 ml incubation bu¡er, the cAMPraising agents and thrombin were added for 20 min (Fig. 3) . As previously reported [7] , forskolin ( þ IBMX) induced vWf release, and potentiated the secretory response to thrombin (Fig. 3A) . In contrast, PGI P release was not reliably detectable in unstimulated cells, and was not stimulated by forskolin. Thrombin-induced PGI P release was inhibited by both 100 Wmol/l IBMX (354 þ 14%, P = 0.01, n = 5) and 10 Wmol/l forskolin (333 þ 7%, P = 0.01, n = 5). Addition of the two agents combined inhibited thrombin-induced PGI P release by 76 þ 6% (P 6 0.01, n = 5). These ¢ndings strongly suggest that increased cellular cAMP inhibits thrombin-induced PGI P release. We also attempted to test the e¡ect of the cAMP analog 8-bromo-cAMP, but unexpectedly this compound interfered with the PGI P assay. Since adenosine induces vWf release in a cAMP-dependent mechanism [8] , we compared the e¡ect of adenosine on vWf and PGI P release (Fig.  3B) . Adenosine both in the absence or presence of IBMX induced vWf release and potentiated the response to thrombin, in agreement with our earlier report [8] . Similar to the pattern seen with forskolin, adenosine failed to induce PGI P release, and inhibited thrombin-induced PGI P release by 29 þ 7% (P = 0.03, n = 4) when added alone and by 62 þ 4% (P = 0.001, n = 4) when added together with IBMX.
E¡ect of iloprost on thrombin-induced PGI P release
The present data with forskolin, IBMX and adenosine indicate that thrombin-induced PGI P release can be inhibited by a rise in cellular cAMP content. Since PGI P itself is a cAMPraising agent, our ¢ndings raise the possibility that PGI P inhibits its own release in an autocrine manner. To test this hypothesis, we compared the e¡ect of iloprost on vWf secretion and PGI P release (Fig. 4) . Iloprost or IBMX was added for 20^40 min prior to a 10 min stimulation with thrombin. Iloprost, alone or in the presence of IBMX, again caused vWf secretion and potentiated thrombin-induced vWf release. In contrast, iloprost caused a 35 þ 9% inhibition of thrombininduced PGI P release (P = 0.02, n = 5). The inhibitory e¡ect of IBMX was even stronger than in the previous experiments (with a 71 þ 7% inhibition), likely due to the longer preincu- Fig. 3 . Di¡erential regulation of vWf secretion and PGI P release by cAMP-raising agents. Con£uent HUVECS grown in 12-well plates were incubated at 37³C in 1.2 ml KRBH. After 10 min, a ¢rst 0.6 ml sample was gently removed. IBMX (100 Wmol/l), forskolin (For, 10 Wmol/l), adenosine (Ado, 100 Wmol/l) and thrombin (Thr, 0.5 U/ml) were then added as indicated. The incubation was continued for 20 min and the supernatants collected for vWf and PGI P assay. For both parameters, release was calculated as the di¡erence in content between the two successive samples, and expressed as a percentage of the response to thrombin alone. Results with forskolin (A) and adenosine (B) derive from two distinct sets of experiments. Results are the mean þ S.E.M. of ¢ve experiments. *P 6 0.05 compared to unstimulated control cells. bation time. However, the inhibitory e¡ect of iloprost and IBMX combined was still even more pronounced (81 þ 5% inhibition), reaching statistical signi¢cance when compared to both thrombin alone or to thrombin/IBMX (P 6 0.05, n = 5).
E¡ect of NO donors on thrombin-induced vWf release
We investigated whether activation of a cGMP-dependent pathway could modulate vWf release in cultured HUVECs. We tested two NO donors, linsidomine (SIN-1) and sodium nitroprusside (SNP). Both agents failed to in£uence basal or thrombin-stimulated vWf release (Fig. 5) . Similar negative results were obtained using the cell-permeant cGMP analogs 8-bromo-cGMP or Sp-8-CPT-cGMPS.
Discussion
Our earlier studies have demonstrated that a cAMP-dependent signaling pathway is involved in the control of regulated vWf release from cultured HUVECs. Forskolin, an activator of adenylate cyclase, and the cAMP analog 8-bromocAMP both induce vWf release and potentiate the secretory response to thrombin [7] . These responses are potentiated by co-incubation with IBMX, an inhibitor of phosphodiesterases which blocks cAMP degradation. Similar responses were observed with receptor-mediated cAMP-raising agents such as epinephrine and adenosine [7, 8] . The e¡ect of cAMP-raising agents is due to regulated release from Weibel-Palade bodies, as indicated by its rapid time course ( 6 30 min). Furthermore, vWf secreted in response to forskolin consists of high molecular weight multimers, typical of regulated release (U.M. Vischer, unpublished observations). Although the secretory responses we observed with receptor-mediated agonists (epinephrine, adenosine) were small, cAMP-dependent vWf secretion is likely to be of physiological signi¢cance. Indeed, in humans epinephrine infusion causes a rise in circulating vWf levels [14] . Further, the rise in plasma vWf levels associated with physical activity in healthy subjects is inhibited by the Ladrenoceptor blocker propranolol [15] .
The main ¢nding of the present study is that iloprost, a prostacyclin agonist known to increase cellular cAMP content [9] , also induced vWf secretion in cultured HUVECs, either when added alone or in combination with IBMX. Moreover, iloprost potentiated the secretory response to thrombin. The secretory response to iloprost is slower than to thrombin, but still occurred within 30 min, indicating secretion from a preformed store rather induction of vWf synthesis and constitutive release. From a physiological point of view, it is unexpected that cAMP-mediated signaling activated by adenosine and prostacyclin stimulates vWf secretion in the endothelium, while it inhibits platelet activation (and by inference vWf release from K-granules). However, exocytosis evoked by cAMP (alone and/or in synergism with intracellular calcium) is not Fig. 4 . E¡ect of iloprost on vWf secretion and PGI P release. Con£u-ent HUVECS grown in 12-well plates were incubated at 37³C in 1.2 ml KRBH. After 10 min, a ¢rst 0.6 ml sample was gently removed. IBMX (100 Wmol/l) and iloprost (Ilo, 1 Wmol/l) were then added as indicated. The incubation was continued for 30^50 min, and thrombin was added for the last 10 min. vWf and PGI P release into the supernatant were measured by ELISA. For both parameters, release was calculated as the di¡erence in content between the two successive samples, and expressed as a percentage of the response to thrombin alone. Results are the mean þ S.E.M. of ¢ve experiments. *P 6 0.05 compared to unstimulated control cells. surprising since it has been observed in many secretory cell systems, such as insulin-secreting L-cells [16] , the exocrine pancreas [17] and others. Our observations are compatible with rat hindlimb perfusion studies showing a potentiating e¡ect of forskolin on vWf secretion induced by the calciummobilizing agents bradykinin and platelet-activating factor [18] .
Prostacyclin infusion is used in the treatment of Raynaud's disease [19] and of primary pulmonary hypertension (PPH) [20] . In the case of PPH, treatment is associated with a marked decrease in vWf levels, as well as a decrease in other endothelial markers such as t-PA and PAI-1 [20, 21] . The present data suggest that prostacyclin does not decrease vWf levels by a direct e¡ect on endothelial vWf release. The e¡ect of prostacyclin is more likely to be due to an indirect e¡ect, such as improved vessel perfusion secondary to its hemodynamic e¡ect, resulting in decreased shear stress [22] . An direct inhibitory e¡ect on platelet vWf release is also a possibility.
vWf secretion, PGI P and NO release are all induced by an increase in [Ca P ] i , raising the issue of the di¡erential regulation of these e¡ector systems. Our ¢ndings demonstrate that while cAMP-mediated signaling induces vWf release, it inhibits PGI P release from cultured HUVECs. This opposite e¡ect was observed in response to forskolin, adenosine and Iloprost. Previous studies have suggested an inhibitory action of cAMP on PGI P release. However, this conclusion was based solely on the inhibitory e¡ect of IBMX [23] . It is now strengthened by our results with the receptor-mediated cAMP-raising agents Iloprost and adenosine. Our observations imply that PGI P can inhibit its own release from endothelial cells, in an autocrine manner. The inhibitory e¡ect of IBMX on PGI P release is greater than that of other cAMP-raising agents. For instance, the e¡ect of IBMX on PGI P release was greater than that of forskolin, while the e¡ect of these two agents on cAMP cellular content is a 2-fold and 4-fold increase respectively [7] . A possible explanation is that IBMX raises not only cAMP but also cGMP levels (by inhibition of cGMP degradation) [24] , which could be involved in the regulation of PGI P release. We did not pursue this hypothesis given the limitations of our culture system for the investigation of cGMP-mediated signaling (see below).
The possible e¡ects of nitric oxide/cGMP-dependent signaling on vWf release are an unsettled issue. Using a rat hindlimb perfusion system, Tranquille and Emeis reported an inhibitory e¡ect of sodium nitroprusside and atrial natriuretic peptide^but not of 8-bromo-cGMP^on vWf and t-PA release [18] . In cat coronary artery segments, thrombin-induced endothelial exocytosis could be inhibited by endothelin-1 in an NO-dependent manner [25] . In contrast, exerciseinduced increases in plasma vWf levels in healthy humans appear to be mediated in part by NO, since they are inhibited by the NO synthase inhibitor L-NMMA [26] . We failed to observe an e¡ect of either NO donors or 8-bromo-cGMP on vWf release in cultured HUVECs. However, this negative result does not exclude a role for NO-mediated signaling in vWf release. Indeed, in contrast to aortic endothelial cells, HUVECs do not express cGMP-dependent protein kinase type I, the activation of which is thought to inhibit thrombin-induced calcium mobilization [27] . These cells thus appear to be insensitive to an inhibitory e¡ect of NO-dependent signaling on vWf release. In summary, our results demonstrate that the prostacyclin analog iloprost, like other cAMP-raising agents, induces vWf release from cultured HUVECs, and potentiates thrombin-induced vWf release. This is a selective e¡ect since cAMP-raising agents^including iloprost^inhibit PGI P release. The latter ¢nding suggests that PGI P can inhibit its own release in an autocrine manner and provides a mechanism for the di¡erential regulation of two endothelial calcium-dependent e¡ector systems.
